Clinical effects of E. coli strain Nissle 1917 in cases of irritable bowel syndrome

In a multicentric study, 41 patients were treated with ­Mutaflor over a period of four weeks.50 ­Mutaflor therapy produced an improvement of the irritable symptoms in a majority of the patients. In particular, meteorism and the pain symptoms associated with it could be improved and the quality of life thus ­increased.

  • 78 % of the patients rated the tolerance of ­Mutaflor therapy as “good” to “very good”.

Pain rating (intensity, duration and frequency) of patients in diaries50

*VAS = Visual analogue scale.

Conclusion

Patients with irritable bowel syndrome who had suffered from infection or had been treated with anti­biotics before the onset of their disease benefited significantly from a ­Mutaflor therapy which had lasted for several weeks.29
Probiotics such as E. coli strain Nissle 1917 are expressly recommended as a ­therapy option in cases of irritable bowel syndrome by the Guideline of the German Society of Digestive and Metabolic ­Diseases (DGVS).51

29) Kruis W et al., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27(4): 467–474.

50) Keller J et al. Reizdarm-Patienten mit Meteorismus als dominantem Symptom profitieren von einer Therapie mit E. coli Nissle 1917 – Ergebnisse einer Pilotstudie. Z Gastroenterol 2010; 48: 955.

51) Layer P. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011; 49: 237–293.

Mutaflor international package insert to download
Mutaflor Suspension international package insert to download